Immutep (ASX:IMM) share price flying 20% on improving trials

The Immutep share price is flying today as the company reported improvements in trials relating to its leading drug IMP321.

| More on:
row of piggy banks with large one receiving injection representing rising Immutep share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is today flying as the company announced a number of results from its ongoing trials. The Immutep share price has gained a huge 20.45% today, rising to 26.5 cents at the time of writing.

What Immutep does

Immutep is a biotechnology company headquartered in Australia. Immutep focuses on personalised bio-therapeutic products for the treatment of cancer. Its main product is eftilagimod alpha (IMP321), a soluble fusion protein, which is in clinical development for the treatment of cancer. Immutep has two other clinical candidates (IMP701 and IMP731) that are fully licensed to major pharmaceutical partners, and a fourth candidate (IMP761) which is in pre-clinical development. 

The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014, the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. It is now dual listed with one listing on the ASX and another as Immutep ADS Representing 10 Ord Shs (NASDAQ: IMMP).

INSIGHT-004 trial

The Immutep share price is soaring higher today as it was announced that the company saw improving results from the INSIGHT-004 trial. The trial is evaluating the combination of Immutep's lead product candidate, IMP321 with a human antibody (avelumab), in 12 patients with different solid tumours, primarily gastrointestinal.

In positive news for the biotech, 41.7% of patients showed a partial response to the combination therapy of IMP321 and avelumab (previously 33%). Furthermore, there was encouraging levels of anti-tumour activity signals in a variety of the cancer indications. These are usually not typically sensitive to immune checkpoint inhibitor (ICI) therapy.

On a final note, the combination of IMP321 and avelumab continues to be safe and well tolerated by patients.

TACTI-002 Study

The TACTI-002 study is being conducted in collaboration with Merck & Co., Inc. (NYSE: MRK). The study is evaluating the combination of IMP321 with Merck & Co's Keytruda drug in patients with neck squamous cell carcinoma or lung cancer.

The study has produced three complete responses, with two in neck squamous cell carcinoma and one in lung cancer. A complete response indicated the complete disappearance of all lesions.

However it must be noted that, despite the improvement, the study has only produced a response in a total of 8 patients out of the 109 in the trial.

What now for the Immutep share price?

The improving results are great news for shareholders as the company seeks to return to its former highs. The Immutep share price has been on an impressive run since its lows in late March this year. The stock is up a huge 165% from its March low of 10 cents.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Technology Shares

After surging 13% yesterday, are TechnologyOne shares a buy, hold or sell according to Macquarie?

Valuations matter when investing, and Macquarie feels no different.

Read more »